Esta web utiliza cookies técnicas, de personalización y de análisis, propias y de terceros, para anónimamente facilitarle la navegación y analizar estadísticas del uso de la web. Obtener más información
Resultados de búsqueda
-
Domino's Pizza
Bell, David E.; Andrews, Phillip; Shelman, MaryCaso HBS-512004-EServicios y operacionesDomino's Pizza is the world's second-largest pizza company with 9,436 stores globally, 95% of which are franchised. Domino's franchisees in the U.S. market were able to purchase fresh dough, cheese, pizza toppings, and other menu ingredients and store supplies directly from the company-owned supply chain system. When commodity prices became more volatile in 2007 and 2008, executives at Domino's changed the way they worked with suppliers and franc...Desde 8,20 €
-
Innovating at AT&T: Partnering to Lead the Broadband Revolution
Applegate, Lynda M.; Andrews, Phillip; Herman, KerryCaso HBS-812124-EIniciativa emprendedoraTo maximize their effectiveness, color cases should be printed in color. In 2010, the U.S. retail market value for next-generation non-handset wirelessly-enabled devices was just over $1 billion. By 2011 it had grown 1,141% to $13.2 billion and was forecast to reach $24.7 billion in 2015. At the same time, user demand for data was surging with the popularity of mobile Internet, e-mail, and messaging, which left carriers scrambling to increase net...Desde 8,20 €
-
Gene Patents (A)
Hamermesh, Richard G.; Kiron, David; Andrews, PhillipCaso HBS-811089-EIniciativa emprendedoraIn March 2010, U.S. District Court Judge Robert Sweet overturned 30 years of legal precedent and ruled that unaltered human genes could not be patented. This case reviews patent law and how it relates to our increasing knowledge of the Human Genome. The case issues deal with the potential implications of Judge Sweet's decision for biotechnology entrepreneurs and investors.Desde 8,20 €
-
Anne Riley: Laid Off
Sucher, Sandra J.; Andrews, PhillipCaso HBS-612008-ELiderazgo y Dirección de personasThis case describes the experience of Anne Riley, a 28 year old private equity analyst, who was laid off in 2008. The case explores the emotions she felt throughout the process and how she handled the experience.Desde 8,20 €
-
Gene Patents (B)
Hamermesh, Richard G.; Andrews, PhillipCaso HBS-812130-EIniciativa emprendedoraThe case updates events since the Court's ruling against Myriad Genetics on March 29, 2010 and should be used in conjunction with Gene Patents (A). On July 29, 2011, a US Appeals Court reversed the prior ruling against Myriad. On September 16, 2011, the first major overhaul of US Patent law in nearly 60 years was signed into law. Among other provisions, the law moved the US to a first to-file priority when granting patents, as was the practice...Desde 5,74 €
-
Corporate Reform Elements of the Dodd-Frank Act
Pozen, Robert C.; Andrews, Phillip; Lane, DavidCaso HBS-311091-EThis note summarizes the four major changes affecting corporate governance that were made by the Dodd-Frank Act of 2010. These changes relate to: advisory notes by shareholders, refinements to board structure, non-disclosure on compensation and tightening up of certain enforcement provisions.Desde 8,20 €
-
The K-Dow Petrochemicals Joint Venture
Subramanian, Guhan; Sebenius, James K.; Andrews, Phillip; Ghosh, Rhea; Krontiris, CharlotteCaso HBS-912002-EIn 2007, the Dow Chemical Company and the Kuwait Petroleum Corporation announced plans to launch a multibillion-dollar joint venture. Later known as K-Dow Petrochemicals, it would be one of the largest manufacturers of chemicals and plastics in the world. Analysts widely hailed the planned joint venture as a game-changing deal for both companies. Shortly after the announcement, cable network CNBC requested an interview with Andrew Liveris, Dow's ...Desde 8,20 €
-
Companion Diagnostics: Uncertainties for Approval and Reimbursement
Hamermesh, Richard G.; Selby, Norman C; Andrews, PhillipCaso HBS-813037-EIniciativa emprendedoraThe FDA approvals of novel therapeutics were seen as signs in the personalized medicine community of real progress in the growth of personalized medicine; The FDA's approval of such drugs, along with companion diagnostics, suggested a shift in thinking and regulatory practices at the agency. Beyond the regulatory questions, many considered the reimbursement system archaic, dispersed, unpredictable, and unnecessarily time consuming. Many questione...Desde 8,20 €
-
U.S. Universities and Technology Transfer
Hamermesh, Richard G.; Lerner, Josh; Andrews, PhillipCaso HBS-812016-EIniciativa emprendedoraTechnology transfer from U.S. universities to industry has increased dramatically in the last 25 years. Reviews the history of technology transfer with particular emphasis on the Bayh-Dole Act of 1980. It then examines how universities responded to Bayh-Dole, the growth of technology transfer offices, and compares how three different universities (MIT, Stanford, and Harvard) approach technology transfer. Provides an overview of the technology tra...Desde 8,20 €